SML1840
YK-3-237
Synonym(s):
B-[2-methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]-boronic acid
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
assay
≥98% (HPLC)
Quality Level
form
powder
color
white to beige
solubility
DMSO: 25 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
YK-3-237 is an activator of sirtuin-1 (SIRT1). YK-3-237 showed anti-proliferative activity toward triple-negative breast cancer, inducing G2/M cell cycle arrest and apoptosis. In a study on renal fibrosis, YK-3-237 caused enhanced expression of α-SMA and fibronectin, suggesting that long-term use of SIRT1 activators may increase the risk or progression of chronic kidney disease.
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Oncotarget, 4(7), 984-994 (2013-07-13)
Many types of mutations in tumor suppressor p53 are oncogenic through gain-of-function. Therefore, targeting mutant p53 (mtp53) is a promising therapeutic approach to fight against many types of cancers. We report here a small molecule compound YK-3-237 that reduces acetylation
The Journal of pharmacology and experimental therapeutics, 354(2), 142-151 (2015-05-30)
Although activation of sirtuin-1 (SIRT1) has been shown to protect the kidney from acute injury, its role in renal fibrosis remains controversial since both inhibition and activation of SIRT1 have been reported to attenuate renal fibrosis. To resolve this conflict
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service